about
The Impact of Timing of Antibiotics on Outcomes in Severe Sepsis and Septic Shock: A Systematic Review and Meta-AnalysisEffect of glucose-insulin-potassium infusion on mortality in critical care settings: a systematic review and meta-analysis.Prehospital treatment of sepsis: what really makes the "golden hour" golden?Pharmacometabolomics of l-carnitine treatment response phenotypes in patients with septic shock.Association between timing of antibiotic administration and mortality from septic shock in patients treated with a quantitative resuscitation protocolOutcomes of patients undergoing early sepsis resuscitation for cryptic shock compared with overt shock.Whole Blood Reveals More Metabolic Detail of the Human Metabolome than Serum as Measured by 1H-NMR Spectroscopy: Implications for Sepsis Metabolomics.Plasma Glycoproteomics Reveals Sepsis Outcomes Linked to Distinct Proteins in Common Pathways.The effect of early quantitative resuscitation on organ function in survivors of septic shock.Early alterations in platelet mitochondrial function are associated with survival and organ failure in patients with septic shock.Biomarkers of endothelial cell activation in early sepsisLactate Clearance in Septic Shock Is Not a Surrogate for Improved Microcirculatory FlowSepsis-induced tissue hypoperfusion.Characteristics and outcomes of patients with vasoplegic versus tissue dysoxic septic shockAssociation between persistent tachycardia and tachypnea and in-hospital mortality among non-hypotensive emergency department patients admitted to the hospital.Sepsis-induced tissue hypoperfusion.Emergency management of severe sepsis and septic shock.The Surviving Sepsis Campaign guidelines 2012: update for emergency physicians.Prognosis of emergency department patients with suspected infection and intermediate lactate levels: a systematic review.Utilizing Geographic Information Systems to Identify Clusters of Severe Sepsis Patients Presenting in the Out-of-Hospital Environment.Randomized trial of inhaled nitric oxide to treat acute pulmonary embolism: The iNOPE trial.Systematic Molecular Phenotyping: A Path Toward Precision Emergency Medicine?Metabolomics as a Driver in Advancing Precision Medicine in Sepsis.Prognostic value of incremental lactate elevations in emergency department patients with suspected infection.The Impact of the Sepsis-3 Septic Shock Definition on Previously Defined Septic Shock Patients.An Emergency Department Validation of the SEP-3 Sepsis and Septic Shock Definitions and Comparison With 1992 Consensus Definitions.Use of Emergency Medicine Milestones as Items on End-of-Shift Evaluations Results in Overestimates of Residents' Proficiency Level.The effect of liver disease on lactate normalization in severe sepsis and septic shock: a cohort study.What Is the Prognosis of Nontraumatic Hypotension and Shock in the Out-of-Hospital and Emergency Department Setting?A decision tree incorporating biomarkers and patient characteristics estimates mortality risk for adults with septic shock.Big data to the rescue of systemic inflammatory response syndrome: is electronic data mining the way of the future?The Challenge and the Promise of Studying Mitochondrial Dysfunction in Humans with Sepsis.Clearing lactate is clearly better…but how much?*.The association of near infrared spectroscopy-derived StO2 measurements and biomarkers of endothelial activation in sepsis.The effect of etomidate on mortality in sepsis remains unclear.Is lactate the "Holy Grail" of biomarkers for sepsis prognosis?Platelet hyperactivation, apoptosis and hypercoagulability in patients with acute pulmonary embolism.Air Ambulance Delivery and Administration of Four-factor Prothrombin Complex Concentrate Is Feasible and Decreases Time to Anticoagulation Reversal.Septic Shock Non-Survivors have Persistently Elevated Acylcarnitines Following Carnitine Supplementation.Whole blood lactate kinetics in patients undergoing quantitative resuscitation for septic shock.
P50
Q28083653-C2D9D576-20CA-40AD-9C7A-7204E7514663Q34054903-4FCE9066-9E37-460B-8759-7DF9678F0236Q35092125-C11E51DC-2BDC-45F4-99B4-70CE9126BC83Q35127737-6E7E22D8-53B5-400B-9988-01EC09A39DA3Q35171210-8FBA623C-C2D3-4572-9616-2CD220B5FE93Q35231436-FA770B23-B63A-42F2-9FFD-69F5C4FA7B08Q35957668-1DCAA6DC-DC37-4B05-BBB6-4C89CEC68849Q36070352-E6C2A1B4-86FE-4A63-9064-1930CF1AACE0Q36268759-047D666F-D742-4A96-B069-586FAB92D6BDQ36403238-F005E4AD-7985-4E3E-856A-7FBCCB1B1C87Q36894829-36C58D2F-2A2F-4647-9758-5ED58F7E7F8AQ37265175-6E0BB693-FA1B-4A9B-BA8B-463E320CEFA6Q37628165-7C01F391-F094-41DA-AF89-A3C0DC778D05Q37696164-37DF5329-53E3-47EB-A601-C2643271A7DEQ37743226-0D7C5748-AC53-484B-A5B5-5A84C8E4BD99Q37840747-C0F09759-BD76-4A68-87A2-8B10CEE94A8EQ38012605-8F43292C-434F-47FC-94EA-9B877C39259FQ38143477-7B42D32D-11BE-4771-AB11-2B1C8025B80AQ38190137-47A6789B-E2FB-4AF5-8D52-700AA522B98CQ38620241-DB961BAB-FE4A-45C4-BA48-9D9D3376FE85Q38813946-64CBD79E-B2D0-4A00-93BA-39D7C074071FQ38854820-FD50F0E5-3AF3-432F-9BC7-ADDE2B2ACDB6Q39386206-AE547F30-B12D-43C2-9071-9039DE7C421EQ40057722-A2938F72-2AE0-4C6B-A363-7E284705EB0AQ40186626-8A10C732-F66B-4E3B-A231-C081459A4659Q40307282-4A7CDA08-415D-4826-B1A4-BF7671DEA363Q40683440-964736BA-9BF6-4D55-9453-EAD00CDF0B65Q41347170-C8E03A28-EED5-4EE1-AE72-F49EF942180AQ41525231-3E2B0354-7906-4447-99ED-7A6E2A5F048DQ42200121-9F3A467A-2D47-4AC2-B1CE-CA62C4CCD020Q42332673-5EB13ED0-7FB1-453D-A417-B5BCEE9B43B5Q43071035-7F8B61D2-0B8F-41C1-BE1F-A5B7F1ABFE32Q43231002-92D63468-E84B-47DE-814A-966874E88786Q44034158-0CA50640-2B60-47D5-9FE9-0BA286E7233AQ45737951-31D271DC-405C-4A55-8513-6949D33051C8Q46047821-B791A561-26A5-43AD-81A0-14F51840A783Q46362996-7BE056A0-32D8-4928-B8BE-E4754B8D8F3DQ48566275-E8C0FC70-1D6E-4296-8FED-5C9D8750B759Q49561103-7F7D0E5A-29B2-46C1-AB60-2D69B57FAFF2Q49581905-25B35731-9E7F-42E5-90CC-E2C3609DB1D0
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Michael A. Puskarich
@ast
Michael A. Puskarich
@en
Michael A. Puskarich
@es
Michael A. Puskarich
@nl
Michael A. Puskarich
@sl
type
label
Michael A. Puskarich
@ast
Michael A. Puskarich
@en
Michael A. Puskarich
@es
Michael A. Puskarich
@nl
Michael A. Puskarich
@sl
prefLabel
Michael A. Puskarich
@ast
Michael A. Puskarich
@en
Michael A. Puskarich
@es
Michael A. Puskarich
@nl
Michael A. Puskarich
@sl
P1053
N-7849-2014
P106
P1153
27467668900
P1960
otF0QdgAAAAJ
P21
P31
P3829
P496
0000-0001-6358-4670